Biotechnology News and Research

RSS

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease.

17 Dec 2013

Mirimus develops enhanced tools for reversible gene suppression

Over the last decades, RNA interference (RNAi) has become an indispensable tool for functional genetic studies by harnessing the power of a cell intrinsic mechanism enabling reversible gene silencing.

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Study: Blue light proves to have powerful bacteria-killing ability

Blue light has proven to have powerful bacteria-killing ability in the laboratory. The potent antibacterial effects of irradiation using light in the blue spectra have now also been demonstrated in human and animal tissues. A series of groundbreaking articles that provide compelling evidence of this effect are published in Photomedicine and Laser Surgery, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers.

16 Dec 2013

MicroBiome Therapeutics announces completion of $1.3M bridge financing

MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.

16 Dec 2013

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cells have a potential to develop into multiple cell types and divide without limit to replenish cells in human body throughout the life of individual.

16 Dec 2013

Aerogen wins Medical Technology Company award for its innovative solutions to healthcare providers

Aerogen, a medical device and drug delivery company has been honoured as the Medical Technology Company of the Year Award 2013. Aerogen's patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of critically ill patients.

16 Dec 2013

Children can reap positive health benefits from increased physical activity

Studies conducted by the Appalachian State University Human Performance Laboratory at the NC Research Campus in Kannapolis, N.C., show that when children increase their level of physical activity, they experience positive health benefits quickly.

13 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

Transport of bacterial substrates through injectisome observed almost in real time

When attacking body cells, bacteria, such as salmonellae or Yersinia (plague pathogens), inject specific bacterial proteins through hollow, syringe-like structures - called injectisomes - into the host cells. These substances reprogram the cells and can thus overcome their defense. From then on, they can infiltrate the cells unhindered in large numbers, and trigger diseases such as typhus, plague, or cholera.

13 Dec 2013

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers.

13 Dec 2013

Health Improvement Institute Founder announces recipients of 2013 Human Research Protection Award

Awards for Excellence in Human Research Protection for 2013 were announced today by Dr. Peter G. Goldschmidt, President and Founder of the Health Improvement Institute.

12 Dec 2013

RBCC, Therakine reach major milestone in the development of new drug delivery technology

Rainbow Coral Corp. and its joint venture partner, Therakine, Ltd., are pleased to announce that they have reached a major new milestone in the development of a revolutionary new drug delivery technology.

12 Dec 2013

Understanding long-term clinical stability in hemophilia patients living with HIV

People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

12 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share.

12 Dec 2013

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.

12 Dec 2013

AlzeCure deploys Vortex tool to develop novel therapies for Alzheimer's disease

Dotmatics, a leading provider of scientific informatics solutions and services to the pharmaceutical and biotechnology industries, announced today that the research foundation AlzeCure, has deployed and integrated the data visualization and analysis tool Vortex. AlzeCure is a novel innovative drug discovery unit that will use Vortex to help in the quest to discover and develop novel therapies for the treatment of Alzheimer's disease and other neurodegenerative disorders.

11 Dec 2013

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease Extension trial.

11 Dec 2013

Biotechnology News and Research

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Mirimus develops enhanced tools for reversible gene suppression

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Study: Blue light proves to have powerful bacteria-killing ability

MicroBiome Therapeutics announces completion of $1.3M bridge financing

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Aerogen wins Medical Technology Company award for its innovative solutions to healthcare providers

Children can reap positive health benefits from increased physical activity

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Transport of bacterial substrates through injectisome observed almost in real time

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Health Improvement Institute Founder announces recipients of 2013 Human Research Protection Award

RBCC, Therakine reach major milestone in the development of new drug delivery technology

Understanding long-term clinical stability in hemophilia patients living with HIV

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

AlzeCure deploys Vortex tool to develop novel therapies for Alzheimer's disease

Prana Biotechnology provides update on IMAGINE PBT2 trial for Alzheimer’s disease

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News